Thomas AJ, et al. - In this work, researchers searched for differences in efficacy of the botulinum toxin neuromodulators onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA for treatment of facial synkinesis. For the management of facial synkinesis, abobotulinumtoxinA seemed to have comparable efficacy to onabotulinumtoxinA and incobotulinumtoxinA up to 4 weeks after treatment. IncobotulinumtoxinA compared to onabotulinumtoxinA had significantly less effect on Synkinesis Assessment Questionnaire score improvement at 4 weeks, perhaps because of the shorter duration of action. When using incobotulinumtoxinA treatment for facial synkinesis, they suggested the necessity for shorter intervals between treatments or larger doses.